CRDF — Cardiff Oncology, Inc.

Is CRDF overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Neutral As of November 17, 2026

Cardiff Oncology, Inc. (CRDF) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.85. The rating moved from Oversold to Neutral on November 17, 2026.

AI analysis

Cardiff Oncology shows characteristics of an early‑stage oncology issuer with limited public financial detail and thin market interest. The combination of likely constrained cash runway, high binary clinical/regulatory outcomes and sector pressure toward convertible financing increases dilution and execution risk. With no clear upcoming catalysts provided and low social/analyst visibility, near‑term moves will be driven by company‑specific news; absent positive developments, downside from current levels is the higher probability path. Monitor cash position, upcoming clinical milestones, and any financing announcements closely.

Key factors

  • Small-cap oncology developer with limited public financial disclosure and no recent EDGAR filing detail provided
  • Likely constrained cash runway typical of pre-revenue/small biotech, increasing probability of near-term financing or dilutive offerings
  • High binary risk tied to clinical readouts or regulatory events; absence of visible upcoming catalysts in the provided data
  • Sector-level pressure from convertible-debt financings and potential dilution in diagnostics/biotech space
  • Low social sentiment and limited analyst coverage noted, implying weak retail/institutional momentum and thin liquidity
  • Broader risk-on market tone could provide short-term uplift, but moves likely driven by company-specific clinical/financing news rather than macro

Risks

  • Need to raise capital leading to equity dilution or unfavorable financing terms
  • Negative or inconclusive clinical trial results or regulatory setbacks
  • High competitive pressure in oncology from larger, better-capitalized firms and more advanced pipelines
  • Low trading liquidity increasing price volatility and widening spreads
  • Market risk: broader biotech drawdowns or adverse funding environment reducing appetite for speculative names
  • Execution risk on partnering or commercialization strategies if any assets progress to later stages

See today's live rating, score and targets

Members see the live hourly rating for CRDF — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.